Analysts from Barclays, Raymond James, and Baird all downgraded their ratings for
Arcturus on Tuesday.
Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021, on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies.
Barclays analyst Gena Wang wrote that the interim data of the vaccine candidate was "disappointing," per
Seeking Alpha.
Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates.
Arcturus released clinical and preclinical data for its COVID-19 vaccine candidate, ARCT-021 on Monday while also announcing that the Singapore Health Sciences Authority approved the vaccine for Phase 2 clinical studies.